ILMN - Illumina, Inc.
Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders.
Illumina advances its sequencing strategy with strong NovaSeq X momentum and clinical demand, but China's weakness and macro pressures cloud the outlook.
SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide.
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President Trump, who brought his CEO contingent and Elon Musk, and President Xi, massive upside earnings and forward guidance from an OG tech and... Here Are Friday's Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina stock jumps after Q1 earnings and revenue beat, with margin expansion and raised 2026 outlook signaling continued growth momentum.
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina (ILMN) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.97 per share a year ago.
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results: Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%) GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9% GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15 On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases "Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Officer of Illumina.
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Caprock Group LLC grew its position in Illumina, Inc. (NASDAQ: ILMN) by 39.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,558 shares of the life sciences company's stock after acquiring an additional 5,764 shares during the quarter.
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Fortis Capital Advisors LLC bought a new position in Illumina, Inc. (NASDAQ: ILMN) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 9,592 shares of the life sciences company's stock, valued at approximately $1,258,000. Several other hedge funds also recently bought and
Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications SAN DIEGO, April 16, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types, DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology.
Illumina, Inc. (NASDAQ: ILMN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the